DI
CRSP icon

Disciplined Investments’s CRISPR Therapeutics CRSP Stock Holding History

Disciplined Investments’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-112
Closed -$7K – 1659
2022
Q3 		$7K Hold
112
– – ﹤0.01% 385
2022
Q2 		$7K Hold
112
– – ﹤0.01% 401
2022
Q1 		$7K Hold
112
– – ﹤0.01% 406
2021
Q4 		$8K Buy
+112
New +$9.79K ﹤0.01% 361

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Disciplined Investments's CRSP Position: Q4 2022 in Review

Disciplined Investments sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 112 shares — an estimated $7K sold.

Disciplined Investments first reported a position in CRSP in Q4 2021 and held it in 4 quarters. The position peaked at $8K in Q4 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

  • Disciplined Investments reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Disciplined Investments sold 112 CRISPR Therapeutics shares in Q4 2022, an estimated $7K.
  • Disciplined Investments first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 4 quarters.
  • Disciplined Investments's CRISPR Therapeutics position peaked at $8K in Q4 2021.
  • 398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Disciplined Investments's 13F filing for Q4 2022, filed 2 Feb 2023.